AGEN Latest Press Releases

-- October 25, 2026 --

Agenus Reports 72% of Patients with Locally Advanced dMMR Colon Cancer Had No Cancer Remaining at Surgery Following Six Weeks of BOT+BAL in Phase 2 NEOASIS Study at ESMO 2026 Business Wire 7:00 AM

-- October 22, 2026 --

Agenus to Provide Third Quarter 2026 Financial Report and Development Update Business Wire 4:30 PM

-- October 9, 2026 --

Agenus to Participate in Chardan's 10th Annual Healthcare Investor Conference Business Wire 3:23 PM

-- October 8, 2026 --

Armenia Grants First Marketing Authorizations for Agenus' BOT+BAL in Previously Treated MSS Metastatic Colorectal Cancer Business Wire 7:30 AM

-- October 3, 2026 --

Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026 Business Wire 10:50 AM

-- October 2, 2026 --

Agenus to Present BOT+BAL Long-Term Survival Data and Translational Research With agenT-797 in Colorectal Cancer at SITC 2026 Business Wire 9:00 AM

-- September 10, 2026 --

Agenus to Present Three-Year Overall Survival Data for BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026 Business Wire 7:30 AM

-- August 31, 2026 --

Agenus to Participate in Upcoming September Investor Conferences Business Wire 7:30 AM

-- August 28, 2026 --

Agenus Announces Peer-Reviewed Publication Linking BOT+BAL's Durable Survival in MSS Metastatic Colorectal Cancer to Its Distinct Immune-Priming Mechanism Business Wire 10:07 AM

-- August 26, 2026 --

Agenus Announces Updated NEST Phase 2 Publication Reporting Deep Pathologic Responses and No Observed Recurrences with Neoadjuvant BOT+BAL in Resectable Colon Cancer Business Wire 10:05 AM

-- August 6, 2026 --

Agenus Reports Second Quarter 2026 Results and Advances Phase 3 ROBBIN Trial of BOT+BAL in Neoadjuvant MSS Colon Cancer Business Wire 7:30 AM

-- July 28, 2026 --

Agenus to Provide Second Quarter 2026 Financial Report and Development Update Business Wire 4:30 PM

-- July 24, 2026 --

GSK's Shingrix (Recombinant Zoster Vaccine) prefilled syringe presentation approved in Canada PRNewswire 6:50 AM

-- July 17, 2026 --

Agenus Announces Three BOT+BAL Presentations Spanning Neoadjuvant and Late-Line Colorectal Cancer and Advanced Sarcomas at ESMO 2026 Business Wire 10:28 AM

-- July 13, 2026 --

Agenus Announces Oversubscribed Private Placement of Up to $340 Million to Advance Registrational ROBBIN Trial of Neoadjuvant BOT+BAL in MSS Colon Cancer Business Wire 6:00 AM

-- July 6, 2026 --

Agenus Reports Landmark BOT+BAL Data Showing 33% Three-Year Overall Survival in Refractory MSS Metastatic Colorectal Cancer Without Active Liver Metastases at ESMO GI 2026 Business Wire 7:30 AM

-- June 25, 2026 --

Agenus Announces Three-Year Survival Data from Phase 1b BOT+BAL Study in MSS Metastatic Colorectal Cancer to be Presented at ESMO GI 2026 Business Wire 7:00 AM

-- June 2, 2026 --

Agenus Announces Virtual 2026 Annual Shareholders Meeting Business Wire 4:30 PM

Market Data Delayed 15 Minutes